Larimar Therapeutics (LRMR) Enterprise Value (2020 - 2026)

Larimar Therapeutics (LRMR) has reported Enterprise Value for 7 consecutive years, with $160.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 245.2% year-over-year to $160.6 million; the trailing twelve-month figure through Jun 2026 stood at $160.6 million (up 245.2% YoY), and the FY2025 full-year result was $179.7 million, up 182.98% from the prior year.
• Enterprise Value fell to $160.6 million in Q2 2026 per LRMR's latest filing, from $179.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at $256.9 million in Q1 2024 and bottomed at -$53.6 million in Q3 2022.
• Historically, Enterprise Value has averaged $86.4 million across 5 years, with a median of $77.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value slumped 144.75% in 2022, then surged 1039.02% in 2023.
• Over 5 years, Enterprise Value stood at -$12.0 million in 2022, then soared by 1039.02% to $113.0 million in 2023, then slumped by 43.79% to $63.5 million in 2024, then soared by 182.98% to $179.7 million in 2025, then decreased by 10.65% to $160.6 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $160.6 million, $179.7 million, and $101.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.